Navigation Links
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009

Data from ACS Phase 2 MDCT Sub-study to be Released Concurrent with AHA Presentation

SAN FRANCISCO, March 31 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an abstract on the Company's Phase 2 clinical trial of VIA-2291 has been accepted for a poster presentation at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009, taking place April 29 - May 1, 2009 in Washington, D.C. The presentation will summarize results of a sub-study of patients from the Company's acute coronary syndrome (ACS) trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with VIA-2291.

Given AHA's embargo policy, the company will announce the data from the MDCT sub-study concurrent with the presentation.

    The poster presentation details are as follows:
          Date / Time:   Friday, May 1, 2009 8:00 a.m. - 10:00 a.m. EDT
          Location:      Omni Shoreham Hotel, Washington, DC
          Presentation:  P555
          Title:         Evaluation of Coronary Artery Atherosclerotic Plaque
                         by Serial 64-Slice Multidetector Computed Tomography
                         in Patients with Recent Acute Coronary Syndrome
                         Treated for 6 Months with 5-Lipoxygenase Inhibitor
          Authors:       Josephine Pressacco, Montreal Heart Institute;
                         Rebecca Taub, VIA Pharmaceuticals, Inc.; Marieve
                         Cossette, Anna Nozza, Janie Paquin, Simon Kouz, Reda
                         Ibrahim, Jean Gregoire, Phillippe L'Allier, Montreal
                         Heart Institute; Ed Chiang, Tilmann M. Brotz, VIA
                         Pharmaceuticals, Inc.; Louise Fortier, Jean-Claude
                         Tardif, Montreal Heart Institute.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit:

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

    Factors that may cause actual results to differ materially from current
    expectations include, but are not limited to:
      -- our ability to borrow additional amounts under the loan from Bay
         City Capital, which is subject to the discretion of Bay City
      -- our ability to obtain necessary financing in the near term,
         including amounts necessary to repay the loan from Bay City Capital
         by the September 14, 2009 maturity date (or earlier if certain
         repayment acceleration provisions are triggered);
      -- our ability to control our operating expenses;
      -- our ability to comply with covenants included in the loan from Bay
         City Capital;
      -- our failure to timely recruit and enroll patients for the FDG-PET
         clinical trial, as well as any future clinical trial;
      -- our failure to obtain sufficient data from enrolled patients that
         can be used to evaluate VIA-2291, thereby impairing the validity or
         statistical significance of our clinical trials;
      -- our ability to successfully complete our clinical trials of VIA-2291
         on expected timetables and the outcomes of such clinical trials;
      -- complexities in designing and implementing cardiovascular clinical
         trials using histological examinations, measurement of biomarkers,
         medical imaging and atherosclerotic plaque bioassays;
      -- the results of our clinical trials, including without limitation,
         with respect to the safety and efficacy of VIA-2291;
      -- if the results of the ACS and CEA studies, upon further review and
         analysis, are revised or negated by authorities or by later stage
         clinical trials;
      -- our ability to obtain necessary FDA approvals;
      -- our ability to successfully commercialize VIA-2291;
      -- our ability to obtain and protect our intellectual property related
         to our product candidates;
      -- our potential for future growth and the development of our product
         pipeline, including the THR beta agonist candidate and the other
         compounds licensed from Roche;
      -- our ability to obtain strategic opportunities to partner and
         collaborate with large biotechnology or pharmaceutical companies to
         further develop VIA-2291;
      -- our ability to form and maintain collaborative relationships to
         develop and commercialize our product candidates;
      -- general economic and business conditions; and
      -- the other risks described under Item IA "Risk Factors" in our Annual
         Report on Form 10-K for the fiscal year ended December 31, 2008 on
         file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):